Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Summary

Merck announced early components of an access strategy for Alimatravir, an investigational once-monthly oral HIV pre-exposure prophylaxis currently in Phase 3 development, to provide broad and sustainable access to the drug.